27 February 2024
27 February 2024
The latest approval is supported by data from the Study 4030 Phase III clinical trial.
The deal will bolster the radiopharmaceutical portfolio of BMS.
The decision on the marketing authorisation for Biogen Qalsody is expected in Q2 2024.
Bayer’s oral tyrosine kinase inhibitor is currently in a Phase I trial estimated to enrol 460 patients.
The positive opinion is based on data from the ALPHA Phase III clinical trial evaluating the safety and efficacy of Voydeya.
IsoTherapeutics offers radiochemistry and bioconjugation development along with contract manufacturing services.
The upcoming Clinical Trial Supply Europe 2024 conference will round-up pharma and biotech delegates to discuss the trends and challenges in clinical trial supply industry.
The Phase II prospective, randomised trial will evaluate three doses of PKM-01 to select the optimal dosage for a Phase III study.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
